AZD 0865

Drug Profile

AZD 0865

Alternative Names: AR-H044277; AZD 865; AZD0865; Front-loaded

Latest Information Update: 10 Aug 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antiulcers
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 28 Jul 2005 Discontinued - Phase-II for Gastro-oesophageal reflux in Europe (PO)
  • 31 May 2005 Data presented at the Digestive Disease Week-2005 (DDW-2005) have been added to the adverse events, pharmacokinetics and Peptic Ulcer Disease pharmacodynamics sections ,
  • 12 Jan 2005 A preclinical study has been added to the Peptic Ulcer Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top